Tecan Collaborates with the Monash Antibody Technologies Facility
News Jul 03, 2007
Tecan and the Monash Antibody Technologies Facility (MATF) at Monash University, Australia, have announced a partnership to create one of the largest and sophisticated monoclonal antibody production systems in the world.
Plans are already underway to develop the system, which will be based around multiple, integrated liquid handling workstations and will fully automate all the stages of the production process.
The importance of monoclonal antibody production is reflected by the breadth of use, which includes research applications, diagnostic applications and use as therapeutic agents.
The MATF claims to be one of the only high throughput production facilities in the world offering custom-made, high-affinity monoclonal antibodies. The new system will increase the production capacity at MATF from original estimates of 500 panels of antibodies a year to potentially 5,000, helping to alleviate the bottleneck of antibody supply experienced by many researchers working on protein function and physiological processes.
The new system, partially funded by the Victorian State Government and Monash University, National Collaborative Research Infrastructure Strategy and the Australian Stem Cell Centre, is a step towards an extensive assay development program planned for 2008, which will further strengthen Monash University’s rising profile as a centre of excellence in the international medical research community.
Carl Severinghaus, Senior Vice President at Tecan, said: “We are delighted to be co-developing this exciting new system with the MATF and look forward to working together on this as well as any future endeavours.”
Tecan’s team of application specialists and engineers will build the system at the company’s headquarters in Männedorf, Switzerland, ready for installation at the MATF in April 2008.
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE